AVRA Medical Robotics Announces its Participation in 10th Annual Meeting of the Society of Robotic Surgery
ORLANDO, Fla., July 08, 2019 — AVRA Medical Robotics, Inc. (the “Company”) (OTCQB: AVMR), an emerging company developing a proprietary software coded system that uses artificial intelligence and machine learning capabilities for the purpose of creating the next generation of fully autonomous medical robotic systems, announced today that its Chief Strategy Officer, D. Nikhil Shah, delivered a presentation at this year’s Annual Meeting of the Society of Robotic Surgery. The meeting took place June 20-23 in Orlando, FL.
Barry Cohen, Chairman and Chief Executive Officer of the Company, commented, “I was extremely pleased that we were able to share the AVRA story at this year’s meeting of the Society of Robotic Surgery. The audience was able to learn about how AVRA is currently developing proprietary algorithms along with specialized software to develop a semi-autonomous operating medical class robot, which should have a relatively quick path to commercialization. Such a device will be a vital solution for our initial market of aesthetics, which focuses on the skin, the largest organ of the human body that experiences many problems that require detailed attention by today’s dermatologists and aestheticians. In addition, our longer-term goal is to then leverage these technologies and create a fully intelligent system with built-in imaging and software programs to offer complete autonomy for medical robotics.”
About AVRA Medical Robotics
AVRA Medical Robotics, Inc., (OTCQB: AVMR) is revolutionizing the practice of medicine by using a proprietary software coded system which incorporates artificial intelligence and machine learning to eventually develop a fully autonomous surgical robotic system. By using an AI enhanced software program, AVRA is creating an intelligent robotic arm that can “robotize” a wide range of medical procedures currently being performed by human hands. AVRA is concentrating its research and development efforts to meet rising expectations of patients and practitioners alike for the precision, safety and speed offered by robotics and artificial intelligence when combined with proven medical devices and surgical instruments. For more information visit the company’s website at www.avramedical.com
-
Most popular related searches
Related news
-
Anuncia Medical Announces the First Successful US Implant of the Company’s Newly Commercially Released ReFlow Mini Flusher Device for Hydrocephalus Patients
Intermountain Primary Children’s Hospital First in the Country to Implant this Next Generation FDA-Cleared Device Company Welcomes Vice President of Sales & Marketing, Mark Geiger, Who Lives with Hydrocephalus Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems and neurocritical care, is pleased to announce the successful first implant of the Company’s...
-
7-year-old Boy Managing His Hydrocephalus with ReFlow Ventricular System “Gen 1” Featured on Charleston’s ABC News 4
After struggling to conceive a child for what felt like ages, Miranda of Moncks County, South Carolina finally fell pregnant - a miracle that quickly turned into horror when she delivered at 24 weeks in late 2015. At just 1 pound and 12 ounces, her son, Sutton, arrived with life-threatening health issues, including hydrocephalus - a neurological disorder caused by an abnormal buildup of cerebrospinal fluid in the brain that affects more than one million Americans.
-
NICE Irreversible Electroporation for Treating Prostate Cancer Announcement
Around half of all men say lack of sexual function is a significant problem to them after prostate cancer intervention, highlighted in an international survey from 32 countries and over 5000 men by the Europa-Uomo group1. Real world evidence is important to understand what is happening to patients in healthcare2, so AngioDynamics welcomed the news last week that the UK’s National Institute for Health and Care Excellence (NICE) Interventional Procedures Advisory Committee (IPAC) upgraded the guidance for...
-
Best HIFU ultrasound facelift machine for medical aesthetic
Today, the medical aesthetic industry has developed to make people more comfortable and safe in their pursuit of beauty. Among the many medical aesthetic procedures available, the best HIFU machine professional is a popular one. It is based on high intensity focused ultrasound technology and provides amazing aesthetic results. This article will reveal the magic of HIFU in a number of sections. Bvlaser is a ODM face lift HIFU machine manufacturer, we have HIFU vaginal tightening machine for sale. Principles of...
-
Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macular degeneration (nAMD) and phase II/III PHOTON trial in diabetic macular edema (DME) QUASAR is expected to enroll around 800 patients in 27 countries Study will add to the robust development program for aflibercept 8 mg, exploring the potential to achieve visual...
Customer comments
No comments were found for AVRA Medical Robotics Announces its Participation in 10th Annual Meeting of the Society of Robotic Surgery. Be the first to comment!